Información del artículo
Resumen
Las crioglobulinemias son una forma especial de vasculitis sistémica secundaria a la presencia de inmunoglobulinas circulantes que se precipitan a temperaturas menores de 37°C y se solubilizan nuevamente con el aumento de la temperatura. Esta precipitación lleva a una vasculitis sistémica de medianos y pequeños vasos, como consecuencia de la presencia de complejos inmunes circulantes y expansión clonal de linfocitos B. Este grupo de entidades debe sospecharse en pacientes con fenómeno de Raynaud, signos clínicos de isquemia periférica en ausencia de enfermedad vascular, cianosis de orejas, nariz y dedos inducida por el frío, vasculitis cutánea, glomerulonefritis membranoproliferativa y gammopatías monoclonales, principalmente. La presencia de crioglobulinas circulantes, la disminución en los niveles de complemento, usualmente de los componentes tempranos como el C4 y el C1q, y la púrpura ortostática son característicos de la enfermedad. El tratamiento de las crioglobulinemias depende de la severidad de los síntomas, la enfermedad de base, la presencia del virus de la hepatitis C y el tipo de crioglobulinas. Las principales causas de muerte en estos individuos son: los compromisos renal, hepático y gastrointestinal, las infecciones, sexo masculino y criocrito mayor a cinco por ciento.
Palabras clave:
crioglobulinemia
crioglobulinas
hepacivirus
Summary
Cryoglobulinemia are a special form of systemic vasculitis secondary to the presence of circulating immunoglobulins that precipitate at temperatures below 37°C and are solubilised again with increasing temperature. This precipitation leads to medium and small-vessel systemic vasculitis as a result of the presence of circulating immune complexes and clonal expansion of B lymphocytes. This group of entities should be suspected in patients with Raynaud phenomenon, clinical signs of ischemia in the absence of peripheral vascular disease, coldinduced cyanosis of ears, nose and fingers, cutaneous vasculitis, membranoproliferative glomerulonephritis, and monoclonal gammopathy. The presence of circulating cryoglobulins, decreased complement levels, usually early components, such as C1q and C4, and orthostatic purpura, are characteristic of the disease. Treatment of cryoglobulinemia depends of severity of the symptoms, underlying disease, the presence of hepatitis C virus and the type of cryoglobulins. The main causes of death in these individuals are: renal, hepatic, gastrointestinal involvements, infections, male and cryocrit more than 5%.
Key words:
cryoglobulinemia
cryoglobulins
hepacivirus
El Texto completo está disponible en PDF
Referencias
[2.]
A.G. Franks.
Skin Manifestations of Internal Disease.
Med Clin N Am, 93 (2009), pp. 1265-1282
[3.]
M. Ramos-Casals, O. Trejo, M. García, R. Cervera, J. Font.
Mixed cryoglobulinemia: new concepts.
Lupus, 9 (2000), pp. 83-91
[4.]
F. Dammacco, D. Sansonmo, C. Piccolli, F.A. Tucci, V. Racanelli.
The cryoglobulins: An overview.
Europ J Clin Invest, 31 (2001), pp. 628-638
[5.]
C. Ferri, M.T. Mascia.
Cryoglobulinemic vasculitis.
Curr Opin Rheumatol, 18 (2006), pp. 54-63
[6.]
A. Dispenzieri, P. Gorevic.
Cryoglobulinemia.
Hematol Oncol Clin N Am, 13 (1999), pp. 1315-1349
[7.]
M. Meltzer, E.C. Franklin.
Cryoglobulinemia: A study of twenty nine patients IgG and IgM cryoglobulins and factors affecting cryoprecipitability.
Am J Med, 40 (1966), pp. 828-836
[8.]
Z.K. Shihabi.
Analysis and general classification of serum cryoglobulins by capillary zone electrophoresis.
Electrophoresis, 17 (1996), pp. 1607-1612
[9.]
Z.K. Shihabi.
Cryoglobulins: an important but neglected clinical test.
Ann Clin Lab Sci, 36 (2006), pp. 395-408
[10.]
M. Trendelenburg, J.A. Schifferli.
Cryoglobulins in chronic hepatitis C virus infection.
Clin Exp Immunol, 133 (2003), pp. 153-155
[11.]
E. Di Stasio, P. Bizzarri, M. Casato, A. Galtieri, M. Fiorilli, L.P. Pucillo.
Cl-regulates cryoglobulin structure: a new hypothesis for the physiopathological mechanism of temperature non-dependent cryoprecipitation.
Clin Chem Lab Med, 42 (2004), pp. 614-620
[12.]
M. Qi, G. Steiger, J.A. Schifferli.
A calcium-dependent cryoglobulin IgM kappa/polyclonal IgG.
J Immunol, 149 (1992), pp. 2345-2351
[13.]
R. Sargur, P. White, W. Egner.
Cryoglobulin evaluation: best practice?.
Ann Clin Biochem, 47 (2010), pp. 8-16
[14.]
J.C. Brouet, J.P. Clauvel, F. Danon, M. Klein, M. Seligmann.
Biologic and clinical significance of cryoglobulins: A report of 86 cases.
Am J Med, 57 (1974), pp. 775-788
[15.]
U. Kallemuchikkal, P.D. Gorevic.
Evaluation of cryoglobulins.
Arch Pathol Lab Med, 123 (1999), pp. 119-125
[16.]
P. Rajvanshi, B. Atac, R. Seno, S. Gupta.
Gallbladder Vasculitis Associated with Type-1 Cryoglobulinemia.
Dig Dis Sci, 46 (2001), pp. 296-300
[17.]
R.G. Owen, S.P. Treon, A. Al-Katib, R. Fonseca, P.R. Greipp, M.L. McMaster, et al.
Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's macroglobulinemia.
Semin Oncol, 30 (2003), pp. 110-115
[18.]
S. Treon.
How I treat Waldenström macroglobulinemia.
Blood, 114 (2009), pp. 2375-2385
[19.]
N.L. Harris, E.S. Jaffe, J. Diebold, G. Flandrin, H.K. Muller- Hermelink, J. Vardiman, et al.
The World Health Organization classification of neoplasticdiseases of the hematopoietic and lymphoid tissues Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia November, 1997.
Ann Oncol, 10 (1999), pp. 1419-1432
[20.]
P. Morel, A. Duhamel, P. Gobbi, M.A. Dimopoulos, M.V. Dhodapkar, J. McCoy, et al.
International prognostic scoring system for Waldenstrom macroglobulinemia.
Blood, 113 (2009), pp. 4163-4170
[21.]
S.P. Treon, M.A. Gertz, M.A. Dimopoulos, A. Anagnostopoulos, J. Blade, A.R. Branagan, et al.
Update on treatment recommendations from the Third International Workshop on Waldenstrom's Macroglobulinemia.
Blood, 107 (2006), pp. 3442-3446
[22.]
M.A. Dimopoulos, M.A. Gertz, E. Kastritis, R. Garcia-Sanz, E.K. Kimby, V. Leblond, et al.
Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia.
J Clin Oncol, 27 (2009), pp. 120-126
[23.]
A. Gatta, C. Giannini, P. Lampertico, P. Pontisso, S. Quarta, A.L. Zignego, et al.
Hepatotropic viruses: new insights in pathogenesis and treatment.
Clin Exp Rheumatol, 26 (2008), pp. S33-S38
[24.]
D. Saadoun, J. Sellam, P. Ghillani-Dalbin, R. Crecel, J.C. Piette, P. Cacoub.
Increased risk of lymphoma and death among patients with non-hepatitis C virus-related mixed cryoglobulinemia.
Arch Intern Med, 166 (2006), pp. 2101-2108
[25.]
G. Monti, P. Pioltelli, F. Saccardo, M. Campanini, M. Candela, G. Cavallero, et al.
Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias.
Arch Intern Med, 165 (2005), pp. 101-105
[26.]
M. Ellis, M. Rathaus, A. Amiel, Y. Manor, A. Klein, M. Lishner.
Monoclonal lymphocyte proliferation and bcl-2 rearrangement in essential mixed cryoglobulinemia.
Eur J Clin Invest, 25 (1995), pp. 833-837
[27.]
J.P. Horcajada, M. García-Bengoechea, G. Cilla, P. Etxaniz, E. Cuadrado, J.I. Arenas.
Mixed cryoglobulinemia in patients with chronic hepatitis C infection: prevalence, significance and relationship with different viral genotypes.
Ann Med, 31 (1999), pp. 352-358
[28.]
L.E. Adinolfi.
Prevalence and incidence of cryoglobulins in chronic hepatitis C patients.
Am J Gastroenterol, 98 (2003), pp. 2568-2569
[29.]
F. Iannuzzella, A. Vaglio, G. Garini.
Management of Hepatitis C Virus-related Mixed Cryoglobulinemia.
Am J Med, 123 (2010), pp. 400-409
[30.]
C. Ferri, M. Sebastiani, D. Giuggioli, M. Cazzato, G. Longombardo, A. Antonelli, et al.
Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients.
Semin Arthritis Rheum, 33 (2004), pp. 355-374
[31.]
A. Tedeschi, C. Baratè, E. Minola, E. Morra.
Cryoglobulinemia.
Blood Rev, 21 (2007), pp. 183-200
[32.]
J.C. Jennette, R.J. Falk, K. Andrassy, P.A. Bacon, J. Churg, W.L. Gross, et al.
Nomenclature of systemic vasculitides Proposal of an international consensus conference.
Arthritis Rheum, 37 (1994), pp. 187-192
[33.]
S. Ninomiya, K. Fukuno, N. Kanemura, N. Goto, S. Kasahara, T. Yamada, et al.
IgG type multiple myeloma and concurrent IgA type monoclonal gammopathy of undetermined significance complicated by necrotizing skin ulcers due to type I cryoglobulinemia.
J Clin Exp Hematopathol, 50 (2010), pp. 71-74
[34.]
G. D’Amico.
Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis.
Kidney Int, 54 (1998), pp. 650-671
[35.]
D. Roccatello, A. Fornasieri, O. Giachino, D. Rossi, A. Beltrame, G. Banfi, et al.
Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis.
Am J Kidney Dis, 49 (2007), pp. 69-82
[36.]
S. Beddhu, S. Bastacky, J.P. Johnson.
The clinical and morphological spectrum of renal cryoglobulinemia.
Medicine, 81 (2002), pp. 398-409
[37.]
L. Daghestani, C. Pomeroy.
Renal manifestations of hepatitis C infection.
Am J Med, 106 (1999), pp. 347-354
[38.]
D. Sansonno, G. Lauletta, M. Montrone, G. Grandaliano, F.P. Schena, F. Dammacco, Hepatitis C.
virus RNA and core protein in kidney glomerular and tubular structures isolated with laser capture micro-dissection.
Clin Exp Immunol, 140 (2005), pp. 498-506
[39.]
A. Tarantino, M. Campise, G. Banfi, R. Confalonieri, A. Bucci, A. Montoli, et al.
Long-term predictors of survival in essential mixed cryoglobulinemia glomerulonephritis.
Kidney Int, 47 (1995), pp. 618-623
[40.]
F. Germignani, G. Melli, C. Inglese, A. Marbini.
Cryoglobulinemiais a frequent cause of peripheral neuropathy in undiagnosed referral patients.
J Peripher Nerv Syst, 7 (2002), pp. 59-64
[41.]
F. Gemignani, F. Brindani, S. Alfieri, T. Giuberti, I. Allegri, C. Ferrari, et al.
Clinical spectrum of cryoglobulinaemic neuropathy.
J Neurol Neurosurg Psychiatry, 76 (2005), pp. 1410-1414
[42.]
S. Boukhris, L. Magy, U. Senga-mokono, V. Loustaud-ratti, J.M. Vallat.
Polyneuropathy with demyelinating features in mixed cryoglobulinemia with hepatitis C virus infection.
Eur J Neurol, 13 (2006), pp. 937-941
[43.]
Z. Kayali, V.E. Buckwold, B. Zimmerman, W.N. Schmidt, C. Hepatitis.
cryoglobulinemia, and cirrhosis: a metaanalysis.
Hepatology, 36 (2002), pp. 978-985
[44.]
D. Saadoun, T. Asselah, M. Resche-Rigon, F. Charlotte, P. Bedossa, D. Valla, et al.
Cryoglobulinemiais associated with steatosis and fibrosis in chronic hepatitis C.
Hepatology, 43 (2006), pp. 1337-1345
[45.]
O. Trejo, M. Ramos-Casals, M. Garcia-Carrasco, J. Yagüe, S. Jiménez, G. de la Red, et al.
Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center.
Medicine, 80 (2001), pp. 252-262
[46.]
P. Vermeersch, K. Gijbels, G. Mariën, R. Lunn, W. Egner, P. White, et al.
A critical appraisal of current practice in the detection, analysis, and reporting of cryoglobulins.
Clin Chem, 54 (2008), pp. 39-43
[47.]
C. Ferri.
Mixed cryoglobulinemia.
Orphanet J Rare Dis, 3 (2008), pp. 1-25
[48.]
C. Ferri, E. Marzo, G. Longobardo, F. Lombardini, L. La Civita, R. Vanacore, et al.
Interferon alpha in mixed cryoglobulinemia patients: A randomized, crossovercontrolled trial.
Blood, 81 (1993), pp. 1132-1136
[49.]
R. Misiani, P. Bellavita, D. Fenili, O. Vicari, D. Marchesi, P.L. Sironi, et al.
Interferon-alpha-2 therapy in cryoglobulinemia patients associated with hepatitis C virus.
N Eng J Med, 330 (1994), pp. 751-756
[50.]
F. Dammacco, D. Sansonno, J.H. Han, V. Shyamala, V. Cornacchiulo, A.R. Iacobelli, et al.
Natural Interferon- a versus its combination with 6-Methyl-Prednisolone in therapy of type II mixed cryoglobulinemia: along term randomized controlled study.
Blood, 84 (1994), pp. 3336-3343
[51.]
P. Cohen, Q.T. Nguyen, P. Deny, F. Ferrière, D. Roulot, O. Lortholary, et al.
Treatment of mixed cryoglobulinemia with recombinant interferon-alpha and adjuvant therapies. A prospective study on 20 patients.
Ann Intern Med, 147 (1996), pp. 81-86
[52.]
M. Casato, V. Agnello, L.P. Pucillo, G.B. Knight, M. Leoni, S. Del Vecchio, et al.
Predictors of long term response to high dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection.
Blood, 90 (1997), pp. 3865-3873
[53.]
C. Mazzaro, G.S. Carniello, R. Colle, P. Doretto, G. Mazzi, M. Crovatto, et al.
Interferon therapy in HCV-positive mixed cryoglobulinemia: viral and host factors contributing to efficacy of therapy.
Ital J Gastroenterol Hepatol, 29 (1997), pp. 343-350
[54.]
J.L. Calleja, A. Albillos, R. Moreno-Otero, I. Rossi, G. Cacho, F. Domper, et al.
Sustained response to interferonalpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinemia.
Aliment Pharmacol Ther, 13 (1999), pp. 1179-1186
[55.]
E. Zuckerman, D. Keren, G. Slobodin, I. Rosner, M. Rozenbaum, E. Toubi, et al.
Treatment of refractory, symptomatic hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha.
J Rheumatol, 27 (2000), pp. 2172-2178
[56.]
C. Donada, A. Crucitti, V. Donadon, L. Chemello, A. Alberti.
Interferon and ribavirin combination therapy in patients with chronic hepatitis C and mixed cryoglobulinemia.
Blood, 92 (1998), pp. 2983-2984
[57.]
C. Mazzaro, F. Zorat, C. Comar, F. Nascimben, D. Bianchini, S. Baracetti, et al.
Interferon plus ribavirin in patients with hepatitis C virus positive mixed cryoglobulinemia resistant to interferon.
J Rheumatol, 30 (2003), pp. 1775-1781
[58.]
A.J. Grillo-López, C.A. White, C. Varns, D. Shen, A. Wei, A. McClure, et al.
Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.
Semin Oncol, 26 (1999), pp. 66-73
[58.]
B. Terrier, D. Launay, G. Kaplanski, A. Hot, C. Larroche, P. Cathébras, et al.
Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French AIR registry.
Arthritis Care Res, 62 (2010), pp. 1787-1795
[59.]
I.M. Ghobrial, D.Z. Uslan, T.G. Call, T.E. Witzig, M.A. Gertz.
Initial increase in the cryoglobulin level after Rituximab therapy for type II cryoglobulinemia secondary to Waldeström macroglobulinemia does not indicate failure of response.
Am J Hematol, 77 (2004), pp. 329-330
[60.]
T. Tallarita, M. Gagliano, D. Corona, G. Giuffrida, A. Giaquinta, D. Zerbo, et al.
Successful combination of Rituximab and plasma exchange in the treatment of cryoglobulinemic vasculitis with skin ulcers: a case report.
Cases J, 2 (2009), pp. 7859
[61.]
A. Della Rossa, F. Marchi, E. Catarsi, A. Tavoni, S. Bombardieri.
Mixed cryoglobulinemia and mortality: a review of the literature.
Clin Exp Rheumatol, 26 (2008), pp. S105-S108
[62.]
D. Landau, S. Scerra, D. Sene, M. Resche-Rigon, D. Saadoun, P. Cacoub.
Causes and Predictive Factors of Mortality in a Cohort of Patients with Hepatitis C Virus-related cryoglobulinemic Vasculitis Treated with Antiviral Therapy.
J Rheumatol, 37 (2010), pp. 615-621
* El trabajo no fue soportado por alguna beca o por fondos de farmacéutica.
Copyright © 2012. Asociación Colombiana de Reumatología
